Reduction in the CD55 and CD59 expression levels is observed in some autoinflammatory diseases and immunodeficiency disorders in which a decrease in complement regulator expression on the cell surface contributes to complement mediated-hemolysis, systemic low-grade inflammation, thrombosis, microangiopathic reactions and renal failure [36]. The gene discussed is CD55; the disease is kidney failure.